Evidence map›Paper›PMID 33723310›Full record

ArticleScientific reports2021

The effects of resveratrol on the expression of VEGF, TGF-β, and MMP-9 in endometrial stromal cells of women with endometriosis.

Tahereh Arablou, Naheed Aryaeian, Sepideh Khodaverdi, Roya Kolahdouz-Mohammadi, Zahra Moradi, Nesa Rashidi, Ali-Akbar Delbandi

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Tahereh ArablouDepartment of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
Naheed AryaeianDepartment of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
Sepideh KhodaverdiEndometriosis Research Center, Iran University of Medical Science, Tehran, Iran.
Roya Kolahdouz-MohammadiDepartment of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
Zahra MoradiDepartment of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Nesa RashidiDepartment of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Ali-Akbar DelbandiDepartment of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. delbandi.ak@iums.ac.ir.
Iran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resveratrol is a phytochemical with anti-angiogenic, anti-inflammatory, and antioxidant properties. The present study has evaluated the effect of resveratrol on the expression of vascular endothelial growth factor (VEGF), transforming growth factor-β (TGF-β) and matrix metalloproteinase-9 (MMP-9) as factors related to endometriosis progression. Thirteen eutopic (EuESCs) and 8 ectopic (EESCs) endometrial stromal cells from women with endometriosis and 11 control endometrial stromal cells (CESCs) were treated with resveratrol (100 µM) for 6, 24 and 48 h. The gene and protein expression levels of VEGF, TGF-β, and MMP-9 were measured using real-time PCR and ELISA methods, respectively. Results showed that the basal gene and protein expression of VEGF and MMP-9 were higher in EESCs compared to EuESCs and CESCs (P < 0.01 to  < 0.001 and P < 0.05 to  < 0.01 respectively). Also, resveratrol treatment decreased the gene and protein expression of VEGF and MMP-9 in EuESCs, EESCs and CESCs (P < 0.05 to  < 0.01 and P < 0.05 to  < 0.01 respectively) and gene and protein expression of TGF-β in EESCs and EuESCs (P < 0.05 to  < 0.01). The effect of resveratrol in reduction of VEGF gene expression was statistically more noticeable in EESCs compared to EuESCs and CESCs (P < 0.05). According to the findings, resveratrol may ameliorate endometriosis progression through reducing the expression of VEGF, TGF-β, and MMP-9 in endometrial stromal cells (ESCs).

Indexed as

AdultCells, CulturedDose-Response Relationship, DrugEndometriosisFemaleGene Expression RegulationHumansMatrix Metalloproteinase 9Middle AgedResveratrolStromal CellsTransforming Growth Factor betaVascular Endothelial Growth Factor AMatrix Metalloproteinase 9MMP9 protein, humanResveratrolTransforming Growth Factor betaVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID33723310
PMCPMC7961000
OpenAlexW3138245363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.